www.fdanews.com/articles/87437-repligen-q4-net-loss-widens-on-lower-revenues-higher-operating-expenses
REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES
June 8, 2006
Thursday morning, Repligen Corp., a biopharmaceutical company, revealed fourth quarter results, reporting a net loss that widened on higher operating expenses and on a 4% decline in revenues.
Trading
Markets